Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: Insights from the CHAMPION PHOENIX (A clinical trial comparing cangrelor to clopidogrel standard therapy in subjects who require percutaneous coronary intervention [PCI])

JACC: Cardiovascular Interventions

Volumn 8, Issue 3, 2015, Pages 424-433

  White, Harvey D ^a   Bhatt, Deepak L ^b   Gibson, C Michael ^c   Hamm, Christian W ^d   Mahaffey, Kenneth W ^e   Price, Matthew J ^f   Steg, Ph Gabriel ^g,h,i,j   Stone, Gregg W ^k   Cortese, Bernardo ^l   Wilensky, Michael ^m   Deliargyris, Efthymios N ⁿ   Liu, Tiepu ⁿ   Prats, Jayne ⁿ   Harrington, Robert A ^e  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^g Institut National de la Sante   (France)

^h BICHAT HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k NewYork Presbyterian Hospital   (United States)

^l Interventional Cardiology   (Italy)

^m Cardiology PC   (United States)

ⁿ MEDICINES COMPANY   (United States)

more..

Author keywords

bivalirudin; cangrelor; CHAMPION PHOENIX; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; ADENOSINE PHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DEVICES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; ODDS RATIO; RISK FACTOR; STENT; TIME;

ADENOSINE MONOPHOSPHATE; AGED; ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HIRUDINS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; RISK FACTORS; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926416293     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.09.025     Document Type: Article

References (21)

1. D.L. Bhatt, G.W. Stone, and K.W. Mahaffey Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
2. G.W. Stone, B.T. McLaurin, and D.A. Cox Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
3. G.W. Stone, J.H. Ware, and M.E. Bertrand Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management. One-year results from the ACUITY trial JAMA 298 2007 2497 2506
4. G.W. Stone, B. Witzenbichler, and G. Guagliumi Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
5. R. Mehran, A.J. Lansky, and B. Witzenbichler Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 2009 1149 1159
6. G.W. Stone, B. Witzenbichler, and G. Guagliumi Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Lancet 377 2011 2193 2204
7. P.G. Steg, S.K. James, and D. Atar ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
8. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 140
9. G.D. Dangas, A. Caixeta, and R. Mehran Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction Circulation 123 2011 1745 1756
10. G. Montalescot, S.D. Wiviott, and E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
11. P.G. Steg, S. James, and R.A. Harrington Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
12. S.J. Brener, K.G. Oldroyd, and A. Maehara Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI Trial) Am J Cardiol 113 2014 1457 1460
13. P.G. Steg, A. van 't Hof, and C.W. Hamm Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
14. A. Shahzad, I. Kemp, and C. Mars Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial Lancet 385 2014 1849 1858
15. S. Leonardi, K.W. Mahaffey, and H.D. White Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial Am Heart J 163 2012 768 776.e2
16. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
17. P. Genereux, G.W. Stone, and R.A. Harrington Impact of Intra-procedural Stent Thrombosis during Percutaneous Coronary Intervention: insights from the CHAMPION PHOENIX trial J Am Coll Cardiol 63 2014 619 629
18. Clemmensen P, Hof Avt, Deliargyris EN, et al. Predictors associated with acute stent thrombosis after primary PCI: The EUROMAX trial. J Am Coll Cardiol 2014;63:A27.
19. D. Alexopoulos, I. Xanthopoulou, and V. Gkizas Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
20. G. Parodi, R. Valenti, and B. Bellandi Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
21. G.J. Dehmer, D. Weaver, and M.T. Roe A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011 J Am Coll Cardiol 60 2012 2017 2031